Overview
Answers to the Questions You May Not be Asking: Treating Ulcerative Colitis Considerate of Patient-centric Factors
Expert Perspectives
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are you aware of the latest evidence-based strategies in ulcerative colitis (UC)? Looking to expand your ability to incorporate patient-centric factors into selection of therapy for UC? Navigate through this novel, interactive self-directed activity designed to optimize your decision making in selection of therapy for UC. View expert perspectives and insights who can help you apply newer strategies such as treat-to-target (T2T) and therapeutic drug monitoring (TDM) for the treatment for your UC patients. Don’t get left behind on the latest UC therapies and treatment strategies.
This activity is intended for gastroenterologists, internal medicine physicians, primary care physicians, and the multidisciplinary team across these different settings involved in the care of patients with UC.
Ulcerative colitis (UC) is a lifelong disease that usually starts in young adulthood. Clinicians managing patients with UC need to become more aware of newer treatment strategies, such as with T2T, TDM, and the role of promising biomarkers. Of concern, more than half (53%) of patients with UC feel that the disease has taken over their life. Clinicians must learn and apply the key steps of shared decision-making (SDM), which include information gathering, support, discussion, and follow-through. Therefore, education on SDM is necessary to bridge the communication and care barriers that persist in the management of UC.
Upon completion of this activity, learners will be able to:
• Outline patient-centric factors that drive selection of therapy for ulcerative colitis
• Apply newer, evidence-based strategies such as treat-to-target (T2T) and therapeutic drug monitoring (TDM) for the treatment of ulcerative colitis
• Outline patient-centric factors that drive selection of therapy for ulcerative colitis
• Apply newer, evidence-based strategies such as treat-to-target (T2T) and therapeutic drug monitoring (TDM) for the treatment of ulcerative colitis
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Millie Long, MD, MPH
Associate Professor
Department of Medicine, Division of Gastroenterology and Hepatology School of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Neilanjan Nandi, MD
Associate Professor of Clinical Medicine
Department of Medicine, Division of Gastroenterology & Hepatology
University of Pennsylvania
Philadelphia, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Millie Long, MD, MPH (Faculty)
Sources of Funding for Research: Eli Lilly, Pfizer, Target RWE
Consulting Agreements: AbbVie, Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus, Roche, Target RWE
Neilanjan Nandi, MD (Faculty)
Sources of Funding for Research: Boehringer-Ingelheim, Bristol Myers Squibb, Janssen
Advisory Board: Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
